Inhibition of human parainfluenza virus type 3 infection by novel small molecules

Area of Science:

• Virology
• Antiviral Research
• Molecular Biology

Background:

• Human parainfluenza virus type 3 (HPIV3) is a significant cause of respiratory illness in infants and children.
• Current therapeutic options for HPIV3 infection are limited, with no approved vaccines or antivirals available.

Purpose of the Study:

• To identify and characterize novel small molecules with antiviral activity against HPIV3.
• To investigate the mechanism of action of identified compounds.

Main Methods:

• Development of a green fluorescent protein (GFP)-tagged HPIV3 infected-cell assay for high-throughput screening.
• Screening of a small molecule library from ChemBridge Diver.
• Confirmation of antiviral activity using plaque assays, Western blot, and Northern blot analyses in cell cultures (CV-1 and A549).
• Mechanism of action studies including time course assays, binding and internalization assays, and minigenome transcription assays.

Main Results:

• Two structurally similar small molecules, C5 and C7, were identified as potent inhibitors of HPIV3.
• C5 and C7 demonstrated significant reduction in viral replication, with IC50 values of 2.36 µM and 0.08 µM, respectively.
• Inhibition was found to occur at the primary transcriptional level of the HPIV3 life cycle.
• The compounds also inhibited vesicular stomatitis virus (VSV) but not poliovirus.

Conclusions:

• C5 and C7 represent promising lead compounds for the development of novel antiviral agents against HPIV3.
• The identified compounds target a critical step in the viral life cycle, offering a new therapeutic strategy.
• Further research into these inhibitors could lead to effective treatments for HPIV3 infections.